期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (8)
Lycopene, a potential bioactive agent, is a non-pro-vitamin A carotenoid recognized as a potent antioxidant. It is extracted from plants like tomatoes......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (4)
Background At present, the treatment of hepatocellular carcinoma (HCC) is disturbed by the treatment failure and recurrence caused by the residual liv......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (9)
Resistance to conventional antitumour therapies and Hypoxia in patients with advanced solid tumours are two major reasons for the failure of conventio......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (9)
The corresponding mRNA vaccines Comirnaty (BNT162b2) and Spikevax (mRNA-1273) have been authorized for emergency use since the COVID-19 outbreak. Most......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (1)
Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (7)
Background HMOX1 has a dual role in cancers, especially involving chemoresistance. We demonstrate that cephalosporin antibiotics exert strong anticanc......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (6)
Aim This study aimed to investigate the biological functions of miRNAs in hepatobiliary tumors as the focus of targeted therapy research. Background H......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (11)
Cervical cancer is a common death-causing cancer among women in developing countries. Majority of the cases are triggered by persistent infections wit......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (7)
Oncolytic viruses (OVs) have become one of the main strategies of cancer biotherapy. They are genetically engineered or naturally occurring viruses th......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (7)
Background: Lung cancer is the leading cause of cancer death in most countries. Although early diagnosis and treatment critically influence prognosis,......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (8)
Pancreatic ductal adenocarcinoma (PDAC) is one of the foremost causes of cancer-related morbidities worldwide. Novel nanotechnology-backed drug delive......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (11)
Background: Neuroblastoma is one of the most common childhood solid tumors. Because tumor suppressor genes are often hypermethylated in cancers, DNA m......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (4)
Aims Development of anticancer agents targeting tubulin protein. Background Tubulin protein is being explored as an important target for anticancer dr......
期刊： CURRENT CANCER DRUG TARGETS, 2023; 23 (6)
Background Thyroid carcinoma (TC) is a common malignant tumor in human and its incidence has been increasing in recent years. Studies have shown that ......
